<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2530">
  <stage>Registered</stage>
  <submitdate>14/10/2009</submitdate>
  <approvaldate>14/10/2009</approvaldate>
  <nctid>NCT00995748</nctid>
  <trial_identification>
    <studytitle>The RECORD Asia-Pacific Atrial Fibrillation Registry</studytitle>
    <scientifictitle>REgistry on Cardiac Rhythm disORDers in Asia-Pacific</scientifictitle>
    <utrn />
    <trialacronym>RECORDAF-AP</trialacronym>
    <secondaryid>DIREG_R_04434</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of therapeutic success by patients in sinus rhythm or heart rate control at target (&lt; 80 beats per minute at rest)</outcome>
      <timepoint>At 12 ± 3 months follow-up</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Comparison of clinical outcomes (Cardiovascular death, Stroke, Myocardial infarction, etc) for patients in rhythm versus rate control strategies</outcome>
      <timepoint>At 12 ± 3 months follow-up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment effectiveness evaluated by the proportion of patients in sinus rhythm</outcome>
      <timepoint>At 1 year follow-up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient presenting with either:

               -  History of atrial fibrillation diagnosed &lt; 1 year by standard Electro-Cardiogram
                  (ECG) or by ECG-Holter monitoring (treated or not or whatever rhythm at
                  inclusion).

               -  New atrial fibrillation diagnosed by standard ECG or by ECG-Holter monitoring at
                  inclusion visit.

          -  Patient eligible for a pharmacological treatment of AF (by rhythm or rate control
             agent).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  AF due to transient cause (thyrotoxicosis, alcohol intoxication, acute phase of
             myocardial infarction, pericarditis, myocarditis, electrocution, pulmonary embolism or
             other pulmonary disease, hydroelectrolytic disorder, metabolic disorder, etc.).

          -  Post cardiac surgery AF (=3 months).

          -  Mentally disabled patients unable to understand or sign the written informed consent.

          -  Patients unable to comply with follow-up visits.

          -  Patients with pacemaker, Implantable Cardioverter Defibrillator (ICD).

          -  Patients scheduled for pulmonary vein ablation, AV node/His bundle ablation, or
             pacemaker implantation.

          -  Patient included in any clinical trial in the previous 3 months.

          -  Pregnant or breastfeeding women.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>2674</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis Administrative Office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Makati City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Primary objective of this registry is to assess the control of Atrial Fibrillation (AF)
      over one year in patients attending clinical or specialized practices.

      The Secondary objectives are:

        -  To describe key demographics and treatment features in AF patients visiting
           cardiologists in various countries in Asia-Pacific.

        -  To establish correlation between control of AF and clinical outcomes.

        -  To establish correlation between treatment strategies and AF control.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00995748</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>